Keynote 224 Results In. Patients were required to have. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on.


Keynote 224 Results In

The abstract ‘ pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (hcc): Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma:

Keynote 224 Results In Images References :

By